Potential surrogate endpoints for prostate cancer survival: analysis of a phase III randomized trial (Q37324245)

19 August 2017

Potential surrogate endpoints for prostate cancer survival: analysis of a phase III randomized trial (English)

1 reference

19 August 2017

phase III clinical trial

0 references

1 reference

Michael E Ray

1

1 reference

19 August 2017

Kyounghwa Bae

2

1 reference

19 August 2017

Maha H A Hussain

3

1 reference

19 August 2017

Gerald E Hanks

4

1 reference

19 August 2017

William U Shipley

5

1 reference

19 August 2017

Howard M Sandler

6

1 reference

19 August 2017

language of work or name

English

0 references

publication date

10 February 2009

1 reference

Journal of the National Cancer Institute

19 August 2017

1 reference

19 August 2017

101

1 reference

19 August 2017

4

1 reference

19 August 2017

228-236

1 reference

Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial

19 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734115

Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734115

Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734115

Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734115

Surrogate endpoints in clinical trials: definition and operational criteria

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734115

Progression-free survival is a surrogate for survival in advanced colorectal cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734115

Analysis of survival by tumor response.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734115

Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734115

Surrogate endpoints: wishful thinking or reality?

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734115

Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734115

Predictors of metastatic disease in men with biochemical failure following radical prostatectomy

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734115

Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734115

Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734115

Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734115

The validation of surrogate endpoints in meta-analyses of randomized experiments

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734115

Definitions of biochemical failure in prostate cancer following radiation therapy.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734115

Time to second prostate-specific antigen failure is a surrogate endpoint for prostate cancer death in a prospective trial of therapy for localized disease

2 September 2018

1 reference

12 December 2020

Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group

1 reference

12 December 2020

Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92-02

1 reference

12 December 2020

Long-Term Results of the M. D. Anderson Randomized Dose-Escalation Trial for Prostate Cancer

1 reference

12 December 2020

Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma

1 reference

12 December 2020

Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31

1 reference

12 December 2020

Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911)

1 reference

12 December 2020

Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer

1 reference

12 December 2020

Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer

1 reference

12 December 2020

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

1 reference

12 December 2020

The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03

1 reference

12 December 2020

Identifiers

DOI

10.1093/JNCI/DJN489

1 reference

19 August 2017

1 reference

19 August 2017

1 reference